PHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regulatory affairs and quality assurance.